MedTrace Logo

Early Vascular Healing in Acute Coronary Syndrome Patients With Different Doses of Rosuvastatin

NCT03007524 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2017-02-23

No results posted yet for this study

Summary

This is a prospective, randomized trial comparing different doses of rosuvastatin in patients with acute coronary syndrome post drug-eluting stents implantation. Through the study, the investigators aim to evaluate the effects of high dose rosuvastatin calcium on "target vessel" endothelialization and "non-target vessel" plaque stability. Moreover, the investigators may provide mechanically evidence of clinical application of high dose rosuvastatin in patients with acute coronary syndrome.

Conditions

  • Acute Coronary Syndrome

Interventions

DRUG

High dose Rosuvastatin

20mg/d qN, at least 6 months

DRUG

Low dose Rosuvastatin

10mg/d qN, at least 6 months

Sponsors & Collaborators

  • Nanjing First Hospital, Nanjing Medical University

    lead OTHER

Principal Investigators

  • Yao-Jun Zhang, PhD · The First Affiliated Hospital with Nanjing Medical University

  • Ze-Ning Jin, PhD · Beijing Anzhen Hospital

  • Fei Ye, PhD · The First Affiliated Hospital with Nanjing Medical University

  • Song Lin, PhD · The First Affiliated Hospital with Nanjing Medical University

  • Bo Xu, MSc · Fu Wai Hospital, Beijing, China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2017-12-31
Completion
2019-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03007524 on ClinicalTrials.gov